For cancer patients the clock is ticking. KIYATEC is working to eliminate time spent on ineffective treatments by using 3D cell culture to individualize each patient’s cancer treatments based on their own live cancer cells. The personalized approach to treatment will lead to healthcare cost savings, better outcomes and a better quality of life for patients.
KIYATEC’s 3D cell culture innovation began with research conducted at Clemson University. Over time, company leadership focused on the technology’s potential to deliver more accurate predictions of patient response to drugs and biologics. In 2014 and 2015, KIYATEC was awarded approximately $3.75M in Phase I and II Small Business Innovation Research (SBIR) contracts from the National Cancer Institute and recently an up to $1.75M Phase II SBIR grant from the National Institute of Biomedical Imaging and Bioengineering.
Now a Graduate, the company has been a part of SCRA’s SC Launch Program since 2007 and has had a profound impact on South Carolina’s Life Sciences industry.